Robert Mabry
About Robert Mabry
Robert Mabry is the Chief Scientific Officer known for his significant contributions to the development of biologic programs, including the approved PD-1 mAb Sintilumab, and has held key roles in several biopharmaceutical companies.
Robert Mabry Chief Scientific Officer
Robert Mabry currently serves as the Chief Scientific Officer. In this capacity, he oversees the scientific development and research of various biologic programs. His work includes contributions to multiple studies, including the development and clinical evaluation of Sintilumab, a PD-1 monoclonal antibody.
Robert Mabry Professional Background
Robert Mabry joined Orna from Takeda Pharmaceuticals, where he was instrumental in the discovery and optimization of biological candidates. He provided strategic guidance to their scientific operations. Prior to Takeda, he was Vice President of Protein Sciences at Cogen Therapeutics, now known as Repertoire Immune Medicines. His leadership in protein engineering, antibody technology, and other related fields has been noted throughout his career.
Robert Mabry Education and Expertise
Robert Mabry holds a Ph.D. in Biochemistry from the University of Texas at Austin. He also earned a Bachelor of Arts in Biology and Biochemistry from Baylor University. His extensive academic background has underpinned his expertise in protein sciences and biologic drug development.
Robert Mabry Industry Experience
Throughout his career, Robert Mabry has held various high-level positions at prominent companies, including Jounce Therapeutics, Adimab, ZymoGenetics, and ImClone Systems. His roles have focused on protein engineering, protein production, and analytics, contributing significantly to advancements in the biopharmaceutical industry.